A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer
- 1 April 2007
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 28 (4), 251-255
- https://doi.org/10.1097/mnm.0b013e3280708ebf
Abstract
To evaluate the changes in differentiation markers and therapeutic effects in all-trans-retinoic acid (ATRA)-treated patients with dedifferentiated thyroid cancer. Between September 2001 and July 2004 eleven patients were analysed retrospectively. They had dedifferentiated thyroid cancers (DTC) (four follicular, five papillary, two oxyphilic) and were selected for treatment with ATRA (1.00+/-0.09 mg x kg x d) for 30 or 60 days. All patients had advanced stage tumours with prior operative and radioiodine treatment. Extensive tumour invasion, distant metastatic spread, and insufficient or non-existent uptake of radioiodine precluded conventional therapeutic options. Changes in I uptake, response of target lesions, and serum thyroglobulin (Tg) levels were measured and compared in these patients before and after ATRA therapy. In 11 patients with DTC, iodine uptake was increased in four and there was a partial response (PR) of target lesions in five patients as well as two patients with stable disease. Tg was assessed in eight patients, in whom two responders showed increased radioiodine uptake or no change and decreased Tg level, as well as PR after ATRA-induced differentiation therapy. ATRA has an effect on the differentiation status of DTC and deserves further investigation.Keywords
This publication has 16 references indexed in Scilit:
- Differentiation-Inducing Therapy for Solid TumorsCurrent Pharmaceutical Design, 2006
- Retinoic Acid and Retinoid X Receptors Are Differentially Expressed in Thyroid Cancer and Thyroid Carcinoma Cell Lines and Predict Response to Treatment with RetinoidsJournal of Clinical Endocrinology & Metabolism, 2004
- Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?Acta Endocrinologica, 2003
- Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Retinoids in chemoprevention and differentiation therapyCarcinogenesis: Integrative Cancer Research, 2000
- Molecular Study of the Sodium–Iodide Symporter (NIS): A New Field in ThyroidologyTrends in Endocrinology & Metabolism, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cellsOncogene, 1999
- Retinoic Acid Increases Sodium/Iodide Symporter mRNA Levels in Human Thyroid Cancer Cell Lines and Suppresses Expression of Functional Symporter in Nontransformed FRTL-5 Rat Thyroid CellsBiochemical and Biophysical Research Communications, 1997
- CDK2 Is a Target for Retinoic Acid-Mediated Growth Inhibition in MCF-7 Human Breast Cancer CellsMolecular Endocrinology, 1997